Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 14/20 | 0.49 |
| ▸ | F10 | P00742 | 11/20 | 0.49 |
| ▸ | F2 | P00734 | 11/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 11/20 | 0.49 |
| ▸ | F3 | P13726 | 6/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13162233 | 0.94 | F7 (0.52) | F7F10F2PRSS1F3 | |
| Trifluoroacetic Acid SCHEMBL3463396 | 0.94 | F7 (0.49) | F7F10F2PRSS1F3 | |
| Trifluoroacetic Acid SCHEMBL3463867 | 0.93 | F7 (0.58) | F7F10F2PRSS1F3 | |
| SCHEMBL3463400 | 0.91 | F7 (0.47) | F7F10F2PRSS1F3 | |
| Trifluoroacetic Acid SCHEMBL3463692 | 0.88 | F7 (0.49) | F7F10F2PRSS1F3 | |
| SCHEMBL13162240 | 0.87 | F7 (0.52) | F7F10F2PRSS1F3 | |
| SCHEMBL13162224 | 0.86 | F7 (0.62) | F7F10F2PRSS1F3 | |
| Trifluoroacetic Acid SCHEMBL3463653 | 0.86 | F7 (0.62) | F7F10F2PRSS1F3 | |
| Trifluoroacetic Acid SCHEMBL3463860 | 0.86 | F7 (0.55) | F7F10F2PRSS1F3 | |
| Trifluoroacetic Acid SCHEMBL3463115 | 0.85 | F7 (0.51) | F7F10F2PRSS1F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240654-A1 | HYDRAZIDE DERIVATIVES | CLARK RICHARD | 2010-09-23 | — | — | US | disclosed |
| US-20080132507-A1 | Hydrazide Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1810965-A1 | HYDRAZIDE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2007-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240654-A1 | HYDRAZIDE DERIVATIVES | H1-10, H1-4, H1-3 | F7 185/4885F10 11/4885F2 19/4885 |
| US-20080132507-A1 | Hydrazide Derivatives | H1-10, H1-4, H1-3 | F7 185/4885F10 11/4885F2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.